Karyopharm reports sustained benefit through 48 weeks in Phase 3 selinexor myelofibrosis trial
KPTI•Karyopharm said Phase 3 SENTRY findings showed ongoing clinical benefit through week 48 with selinexor combined with ruxolitinib. It will present the findings at the American Society of Hematology meeting on Dec. 13, 2026.
1. SENTRY trial findings
Karyopharm Therapeutics will present Phase 3 SENTRY findings on Dec. 13 at the American Society of Hematology meeting. The findings show ongoing clinical benefit through week 48 with selinexor combined with ruxolitinib.
2. Other meeting presentations
Early Phase 2 SENTRY-2 results support selinexor monotherapy activity in JAK inhibitor-naïve myelofibrosis and will be presented Dec. 12. A Dec. 12 poster will feature updated Phase 1b/2 STOMP results evaluating selinexor with mezigdomide and dexamethasone in relapsed or refractory multiple myeloma.
